Latest Articles

Publication Date
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of pembrolizumab for locally advanced uterine cervical cancer, and durvalumab and olaparib for advanced or recurrent endometrial cancer in Japan - springermedicine.com

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of pembrolizumab for locally advanced uterine cervical cancer, and durvalumab and olaparib for advanced …

Published: Dec. 28, 2024, 12:47 p.m.
Durvalumab Plus Olaparib Approaches EU Approval for pMMR Advanced or Recurrent Endometrial Cancer - OncLive

Durvalumab Plus Olaparib Approaches EU Approval for pMMR Advanced or Recurrent Endometrial Cancer OncLive

Published: July 1, 2024, 7 a.m.
Frontline Durvalumab/Chemo, Then Maintenance Durvalumab ± Olaparib, Improves ORR in Endometrial Cancer - OncLive

Frontline Durvalumab/Chemo, Then Maintenance Durvalumab ± Olaparib, Improves ORR in Endometrial Cancer OncLive

Published: June 21, 2024, 7 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!